Home / SHJBF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does SHJBF make money? Does SHJBF have pricing power? What's the Earnings Whisper? Will SHJBF profit more as the business scales? What is SHJBF's management track record? Is SHJBF's current price justified?

Shanghai Junshi Biosciences Co., Ltd.

$3.35 +$0.27 (+8.77%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$3.35

Day Range

$3.08$3.35

Year Range

$1.97$4.23

Market Cap

4.84B

AVG Volume

Trailing/Forward PE

-74.86/30

PEG ratio

0.53

Dividend Yield

Next Earnings Date

2026-10-23

Primary Exchange

Other OTC

Revenue (CNY)

SHJBF Revenue (CNY) by quarter
Period	Revenue (CNY)
26 Q2	965.96M
26 Q1	719.34M
25 Q4	682.38M
25 Q3	637.05M
25 Q2	667.79M
25 Q1	500.59M
24 Q4	677.12M
24 Q3	470.54M
24 Q2	405.25M
24 Q1	376.99M

Net Income (CNY)

SHJBF Net Income (CNY) by quarter
Period	Net Income (CNY)
26 Q2	42.05M
26 Q1	-20.37M
25 Q4	-274.6M
25 Q3	-183M
25 Q2	-177.82M
25 Q1	-234.88M
24 Q4	-354.16M
24 Q3	-281.81M
24 Q2	-362.66M
24 Q1	-284.41M

Operating Income (CNY)

SHJBF Operating Income (CNY) by quarter
Period	Operating Income (CNY)
26 Q2	-41.87M
26 Q1	-110.18M
25 Q4	-319.13M
25 Q3	-178M
25 Q2	-193.3M
25 Q1	-281.72M
24 Q4	-369.7M
24 Q3	-293.44M
24 Q2	-322.39M
24 Q1	-292.84M

EBITDA (CNY)

SHJBF EBITDA (CNY) by quarter
Period	EBITDA (CNY)
26 Q2	36.26M
26 Q1	-110.18M
25 Q4	-244.2M
25 Q3	-171M
25 Q2	-134.43M
25 Q1	-205.05M
24 Q4	-365.38M
24 Q3	-214.81M
24 Q2	-255.04M
24 Q1	-247.8M

Cash Flows (CNY)

SHJBF Cash Flows (CNY) by quarter
Period	Cash Flows (CNY)
26 Q2	-193.96M
26 Q1	-189.68M
25 Q4	-398.19M
25 Q3	-229M
25 Q2	-457.61M
25 Q1	-185.53M
24 Q4	-390.6M
24 Q3	-494.04M
24 Q2	-247.06M
24 Q1	-591.74M

EPS (CNY)

SHJBF EPS (CNY) by quarter
Period	EPS (CNY)
26 Q2	0.04
26 Q1	-0.02
25 Q4	-0.27
25 Q3	-0.18
25 Q2	-0.18
25 Q1	-0.24
24 Q4	-0.36
24 Q3	-0.04
24 Q2	-0.37
24 Q1	-0.29

Expenses (CNY)

SHJBF Expenses (CNY) by quarter
Period	Expenses (CNY)
26 Q2	784.95M
26 Q1	919.14M
25 Q4	355.58M
25 Q3	943.37M
25 Q2	867.87M
25 Q1	831.9M
24 Q4	938.62M
24 Q3	912.13M
24 Q2	942.07M
24 Q1	804.69M

Cash & Debt (CNY)

SHJBF Cash & Debt (CNY) by quarter
Period	Cash & Debt (CNY)
26 Q2	3.7B
26 Q1	4.54B
25 Q4	3.22B
25 Q3	3.27B
25 Q2	3.51B
25 Q1	3.02B
24 Q4	2.93B
24 Q3	3.04B
24 Q2	3.31B
24 Q1	4.56B

Debt ratios

SHJBF Debt ratios by quarter
Period	Debt ratios
26 Q2	-4.53
26 Q1	-2.17
25 Q4	-1.23
25 Q3	-0.36
25 Q2	0.01
25 Q1	0.23
24 Q4	0
24 Q3	0.18
24 Q2	0.44
24 Q1	0.81

Margins

SHJBF Margins by quarter
Period	Margins
26 Q2	81.26%
26 Q1	79.76%
25 Q4	74.99%
25 Q3	81.72%
25 Q2	76.57%
25 Q1	81.24%
24 Q4	70.73%
24 Q3	76.04%
24 Q2	74.66%
24 Q1	71.19%

Return on Capital

SHJBF Return on Capital by quarter
Period	Return on Capital
26 Q2	0.68%
26 Q1	-0.34%
25 Q4	-4.53%
25 Q3	-2.91%
25 Q2	-2.78%
25 Q1	-4.14%
24 Q4	-5.97%
24 Q3	-4.5%
24 Q2	-5.48%
24 Q1	-4.05%

Shares Outstanding

SHJBF Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	1.03B
26 Q1	1.03B
25 Q4	1.03B
25 Q3	1.03B
25 Q2	986.57M
25 Q1	978.65M
24 Q4	983.54M
24 Q3	984.87M
24 Q2	985.01M
24 Q1	985.01M

Book Value Per Share (CNY)

SHJBF Book Value Per Share (CNY) by quarter
Period	Book Value Per Share (CNY)
26 Q2	6
26 Q1	5.91
25 Q4	5.87
25 Q3	6.13
25 Q2	6.48
25 Q1	5.79
24 Q4	6.03
24 Q3	6.36
24 Q2	6.72
24 Q1	7.13

Total Assets (CNY)

SHJBF Total Assets (CNY) by quarter
Period	Total Assets (CNY)
26 Q2	14.26B
26 Q1	14.1B
25 Q4	12.39B
25 Q3	11.68B
25 Q2	11.68B
25 Q1	10.9B
24 Q4	10.78B
24 Q3	10.84B
24 Q2	11.01B
24 Q1	12.03B

Free Cash Flow Yield

SHJBF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-5.53%
Sep 26	-5.53%
Aug 26	-5.51%
Aug 26	-5.52%
Aug 26	-5.5%
Aug 26	-5.5%
Jul 26	-5.49%
Jul 26	-5.48%
Jul 26	-5.47%
Jul 26	-5.47%
Jul 26	-5.46%
Jun 26	-5.41%
Jun 26	-5.43%
Jun 26	-5.43%
Jun 26	-5.43%
May 26	-5.43%
May 26	-5.41%
May 26	-5.4%
May 26	-6.03%
May 26	-6.01%
Apr 26	-6%
Apr 26	-6.02%
Apr 26	-6.01%
Apr 26	-5.96%
Mar 26	-5.94%
Mar 26	-5.96%
Mar 26	-5.95%
Mar 26	-5.95%
Feb 26	-5.98%
Feb 26	-5.94%
Feb 26	-5.94%
Feb 26	-5.91%
Jan 26	-5.9%
Jan 26	-5.89%
Jan 26	-5.89%
Jan 26	-5.88%
Jan 26	-5.72%
Dec 25	-7.39%
Dec 25	-7.36%
Dec 25	-5.19%
Dec 25	-5.18%
Nov 25	-5.17%
Nov 25	-5.15%
Nov 25	-5.16%
Nov 25	-5.14%
Oct 25	-5.14%
Oct 25	-5.14%
Oct 25	-5.14%
Oct 25	-5.13%
Oct 25	-5.14%
Sep 25	-4.8%
Sep 25	-9.6%
Sep 25	-9.59%
Sep 25	-9.58%
Aug 25	-9.58%
Aug 25	-9.54%
Aug 25	-9.51%
Aug 25	-9.51%
Aug 25	-9.47%
Jul 25	-9.53%
Jul 25	-9.52%
Jul 25	-9.53%
Jul 25	-9.53%
Jun 25	-12.4%
Jun 25	-12.43%
Jun 25	-12.39%
Jun 25	-12.37%
May 25	-12.36%
May 25	-12.39%
May 25	-12.34%
May 25	-12.29%
May 25	-12.23%
Apr 25	-12.21%
Apr 25	-12.19%
Apr 25	-12.2%
Apr 25	-12.22%
Mar 25	-12.73%
Mar 25	-12.75%
Mar 25	-12.77%
Mar 25	-12.78%
Feb 25	-12.69%
Feb 25	-12.75%
Feb 25	-12.75%
Feb 25	-12.68%
Jan 25	-12.75%
Jan 25	-12.76%
Jan 25	-12.62%
Jan 25	-12.61%
Jan 25	-12.63%
Dec 24	-19.81%
Dec 24	-19.81%
Dec 24	-19.87%
Dec 24	-19.88%
Nov 24	-19.96%
Nov 24	-19.95%
Nov 24	-19.99%
Oct 24	-20.4%
Oct 24	-20.46%
Oct 24	-20.6%
Sep 24	-23.76%

Price to Sales

SHJBF Price to Sales by quarter
Period	Price to Sales
Sep 26	8.52
Sep 26	8.52
Aug 26	8.54
Aug 26	8.53
Aug 26	8.56
Aug 26	8.57
Jul 26	8.57
Jul 26	8.6
Jul 26	8.6
Jul 26	8.6
Jul 26	8.62
Jun 26	9.45
Jun 26	9.41
Jun 26	9.4
Jun 26	9.4
May 26	9.4
May 26	9.44
May 26	9.46
May 26	8.46
May 26	8.5
Apr 26	8.51
Apr 26	8.48
Apr 26	8.5
Apr 26	8.57
Mar 26	8.57
Mar 26	8.54
Mar 26	8.55
Mar 26	8.55
Feb 26	8.5
Feb 26	8.56
Feb 26	8.56
Feb 26	8.6
Jan 26	8.62
Jan 26	8.63
Jan 26	8.64
Jan 26	8.65
Jan 26	8.9
Dec 25	8.92
Dec 25	8.97
Dec 25	12.71
Dec 25	12.74
Nov 25	12.75
Nov 25	12.8
Nov 25	12.79
Nov 25	12.83
Oct 25	12.82
Oct 25	12.83
Oct 25	12.84
Oct 25	12.85
Oct 25	12.83
Sep 25	13.36
Sep 25	6.68
Sep 25	6.69
Sep 25	6.7
Aug 25	6.69
Aug 25	6.73
Aug 25	6.74
Aug 25	6.74
Aug 25	6.77
Jul 25	6.73
Jul 25	6.74
Jul 25	6.73
Jul 25	6.73
Jun 25	7.2
Jun 25	7.19
Jun 25	7.21
Jun 25	7.22
May 25	7.23
May 25	7.21
May 25	7.24
May 25	7.26
May 25	7.3
Apr 25	7.31
Apr 25	7.33
Apr 25	7.32
Apr 25	7.31
Mar 25	8.04
Mar 25	8.02
Mar 25	8.01
Mar 25	8.01
Feb 25	8.06
Feb 25	8.03
Feb 25	8.03
Feb 25	8.07
Jan 25	8.03
Jan 25	8.02
Jan 25	8.11
Jan 25	8.12
Jan 25	8.1
Dec 24	14.55
Dec 24	14.55
Dec 24	14.51
Dec 24	14.5
Nov 24	14.44
Nov 24	14.45
Nov 24	14.42
Oct 24	14.13
Oct 24	14.09
Oct 24	14
Sep 24	13.6

Price to Book

SHJBF Price to Book by quarter
Period	Price to Book
Sep 26	3.8
Sep 26	3.8
Aug 26	3.81
Aug 26	3.81
Aug 26	3.82
Aug 26	3.82
Jul 26	3.82
Jul 26	3.84
Jul 26	3.84
Jul 26	3.84
Jul 26	3.85
Jun 26	3.88
Jun 26	3.86
Jun 26	3.86
Jun 26	3.86
May 26	3.86
May 26	3.88
May 26	3.89
May 26	3.47
May 26	3.49
Apr 26	3.49
Apr 26	3.48
Apr 26	3.49
Apr 26	3.52
Mar 26	3.38
Mar 26	3.37
Mar 26	3.37
Mar 26	3.37
Feb 26	3.35
Feb 26	3.38
Feb 26	3.38
Feb 26	3.39
Jan 26	3.4
Jan 26	3.41
Jan 26	3.41
Jan 26	3.41
Jan 26	3.51
Dec 25	3.23
Dec 25	3.25
Dec 25	4.61
Dec 25	4.62
Nov 25	4.62
Nov 25	4.64
Nov 25	4.63
Nov 25	4.65
Oct 25	4.65
Oct 25	4.65
Oct 25	4.65
Oct 25	4.66
Oct 25	4.65
Sep 25	4.84
Sep 25	2.42
Sep 25	2.42
Sep 25	2.43
Aug 25	2.42
Aug 25	2.44
Aug 25	2.44
Aug 25	2.44
Aug 25	2.45
Jul 25	2.44
Jul 25	2.44
Jul 25	2.44
Jul 25	2.44
Jun 25	2.34
Jun 25	2.34
Jun 25	2.35
Jun 25	2.35
May 25	2.35
May 25	2.34
May 25	2.35
May 25	2.36
May 25	2.37
Apr 25	2.38
Apr 25	2.38
Apr 25	2.38
Apr 25	2.38
Mar 25	2.25
Mar 25	2.24
Mar 25	2.24
Mar 25	2.24
Feb 25	2.25
Feb 25	2.24
Feb 25	2.24
Feb 25	2.26
Jan 25	2.24
Jan 25	2.24
Jan 25	2.27
Jan 25	2.27
Jan 25	2.27
Dec 24	1.35
Dec 24	1.35
Dec 24	1.34
Dec 24	1.34
Nov 24	1.34
Nov 24	1.34
Nov 24	1.33
Oct 24	1.31
Oct 24	1.3
Oct 24	1.29
Sep 24	1.22

No video analysis for this stock yet. Request one from our team.

News: SHJBF

globenewswire.com · 21 Jul 2026

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.

AI Analysis

Shanghai Junshi Biosciences Co., Ltd.

Video analysis: SHJBF

News: SHJBF

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Similar companies